Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild‐type and TERT promoter mutation histological grade 2/3 gliomas: An extension retrospective analysis of a randomized controlled trial
Cancer · 2025
DOI: 10.1002/cncr.70171 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Cancer, 2025. Verfasst von Jing Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Temozolomide, Telomerase, Isocitrate Dehydrogenase, Glioma. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
The long‐term results confirmed that the OS and PFS benefits from the RT‐TMZ exceeded those of the RT alone in patients with IDH‐wt/pTERTmut gliomas with tolerable toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
- Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
- National Clinical Research Center for Neurological Diseases, Beijing, China.
ORCID-Profile: Peng Wang, Xiaoguang Qiu
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Zhang, J., Wang, P., Ren, Y., Chen, L., Feng, J., Liu, F., Deng, K., Bao, Z., Qiu, X., & Liu, Y. (2025). Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild‐type and TERT promoter mutation histological grade 2/3 gliomas: An extension retrospective analysis of a randomized controlled trial. Cancer. https://doi.org/10.1002/cncr.70171
Vancouver
Zhang J, Wang P, Ren Y, Chen L, Feng J, Liu F, et al. Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild‐type and TERT promoter mutation histological grade 2/3 gliomas: An extension retrospective analysis of a randomized controlled trial. Cancer. 2025. doi:10.1002/cncr.70171
BibTeX
@article{Zhang2025,
author = {Zhang, Jing and Wang, Peng and Ren, Yin and Chen, Li and Feng, Jin and Liu, Fei and Deng, Kaiwen and Bao, Zhaoshi and Qiu, Xiaoguang and Liu, Yanwei},
title = {Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild‐type and TERT promoter mutation histological grade 2/3 gliomas: An extension retrospective analysis of a randomized controlled trial},
journal = {Cancer},
year = {2025},
doi = {10.1002/cncr.70171}
}
EUVIMED